TY - JOUR
T1 - Enzymatic cross-linking of collagens in organ fibrosis - resolution and assessment
AU - Pehrsson, Martin
AU - Mortensen, Joachim Hog
AU - Manon-Jensen, Tina
AU - Bay-Jensen, Anne-Christine
AU - Karsdal, Morten Asser
AU - Davies, Michael Jonathan
PY - 2021
Y1 - 2021
N2 - Introduction: Enzymatic cross-linking of the collagens within the extracellular matrix (ECM) catalyzed by enzymes such as lysyl oxidase (LOX) and lysyl oxidase like-enzymes 1-4 (LOXL), transglutaminase 2 (TG2), and peroxidasin (PXDN) contribute to fibrosis progression through extensive collagen cross-linking. Studies in recent years have begun elucidating the important role of collagen cross-linking in perpetuating progression of organ fibrosis independently of inflammation through an increasingly stiff and noncompliant ECM. Therefore, collagen cross-linking and the cross-linking enzymes have become new targets in anti-fibrotic therapy as well as targets of novel biomarkers to properly assess resolution of the fibrotic ECM. Areas covered: The enzymatic actions of enzymes catalyzing collagen cross-linking and their relevance in organ fibrosis. Potential biomarkers specifically quantifying proteolytic fragments of collagen cross-linking is discussed based on Pubmed search done in November 2020 as well as the authors knowledge. Expert opinion: Current methods for the assessment of fibrosis involve the use of invasive and/or cumbersome and expensive methods such as tissue biopsies. Thus, an unmet need exists for the development and validation of minimally invasive biomarkers of proteolytic fragments of cross-linked collagens. These biomarkers may aid in the development and proper assessment of fibrosis resolution in coming years.
AB - Introduction: Enzymatic cross-linking of the collagens within the extracellular matrix (ECM) catalyzed by enzymes such as lysyl oxidase (LOX) and lysyl oxidase like-enzymes 1-4 (LOXL), transglutaminase 2 (TG2), and peroxidasin (PXDN) contribute to fibrosis progression through extensive collagen cross-linking. Studies in recent years have begun elucidating the important role of collagen cross-linking in perpetuating progression of organ fibrosis independently of inflammation through an increasingly stiff and noncompliant ECM. Therefore, collagen cross-linking and the cross-linking enzymes have become new targets in anti-fibrotic therapy as well as targets of novel biomarkers to properly assess resolution of the fibrotic ECM. Areas covered: The enzymatic actions of enzymes catalyzing collagen cross-linking and their relevance in organ fibrosis. Potential biomarkers specifically quantifying proteolytic fragments of collagen cross-linking is discussed based on Pubmed search done in November 2020 as well as the authors knowledge. Expert opinion: Current methods for the assessment of fibrosis involve the use of invasive and/or cumbersome and expensive methods such as tissue biopsies. Thus, an unmet need exists for the development and validation of minimally invasive biomarkers of proteolytic fragments of cross-linked collagens. These biomarkers may aid in the development and proper assessment of fibrosis resolution in coming years.
KW - Collagen cross-linking
KW - lysyl oxidase
KW - transglutaminse 2
KW - peroxidasin
KW - organ fibrosis
KW - fibrosis resolution
KW - cross-linking biomarkers
KW - LYSYL HYDROXYLASE 3
KW - EXTRACELLULAR TRANSGLUTAMINASE 2
KW - IDIOPATHIC PULMONARY-FIBROSIS
KW - BONE MORPHOGENETIC PROTEIN-1
KW - CAUSES HYPERELASTOSIS CUTIS
KW - GLYCATION END-PRODUCTS
KW - GROWTH-FACTOR-BETA
KW - TISSUE TRANSGLUTAMINASE
KW - TERMINAL PROPEPTIDE
KW - INTESTINAL FIBROSIS
U2 - 10.1080/14737159.2021.1962711
DO - 10.1080/14737159.2021.1962711
M3 - Review
C2 - 34330194
VL - 21
SP - 1049
EP - 1064
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 10
ER -